What Benostan Treats: Main Uses and Benefits

Benostan (Mefenamic Acid) is commonly used to relieve mild-to-moderate pain and inflammation. It is applied across therapeutic domains where additional symptomatic support is needed, primarily for symptoms related to inflammatory or irritative states.

This medication is relevant for easing symptoms that interfere with daily functioning, including conditions such as primary dysmenorrhea (menstrual cramps) and various forms of acute musculoskeletal pain and discomfort. It is also commonly used to help with managing pain that accompanies fever, offering symptomatic assistance across multiple areas.

“Benostan is used in situations involving certain distressing symptoms, contributing to easing discomfort during periods of heightened symptoms.”

It offers symptomatic relief that may help patients cope more steadily with difficult episodes. For example, it is often used when symptoms intensify, such as following minor procedures like dental work. This approach helps maintain a sense of stability when symptoms are more noticeable.

---

Quick Fact	Relief for Symptom
Primary Focus	Acute, Mild-to-Moderate Pain
Specialized Use	Menstrual Cramps (Dysmenorrhea)
Supportive Role	Pain and Fever

---

Regulatory References

1. NIH MedlinePlus overview

The eligibility profile for this medicine is based on the authoritative government regulatory documents for Benzonatate, a structurally related and widely regulated non-narcotic antitussive agent.

Eligibility and Non-Eligibility Rules

Eligibility Status	Population or Condition	Regulatory Basis
Contraindicated	Known hypersensitivity to benzonatate or related compounds (such as ester-type local anesthetics like procaine or tetracaine).	Strict Exclusion
Contraindicated	Children below 10 years of age.	Safety and effectiveness have not been established.
Conditional Use	Pregnant women	Classified as Pregnancy Category C. Should be given only if clearly needed, as it is unknown whether the drug can cause fetal harm.
Caution Advised	Nursing mothers	Not known whether the drug is excreted in human milk; caution should be exercised.

---

Use of this medicine is limited to adults and adolescents aged 10 years and older. The most significant restriction is the absolute exclusion of patients with a documented allergy to the drug or chemically similar anesthetics. Official labeling strictly prohibits use in children under 10 due to unestablished safety and the reported risk of severe toxicity and death from accidental ingestion in this age group.

Interactions with Other Medicines and Products

The interaction profile for Benostan (Mefenamic Acid) is defined by official regulatory documents detailing pharmacodynamic and pharmacokinetic effects on co-administered substances. This information strictly outlines documented restrictions and required patient monitoring.

Prohibited and Restricted Combinations

Category	Restriction
Surgical Procedure	Contraindicated for peri-operative pain after Coronary Artery Bypass Graft (CABG) surgery.
Systemic Medicines	Co-administration with other systemic non-aspirin NSAIDs should be avoided due to the increased risk of adverse events.

Clinically Relevant Interactions

The medicine may cause significant documented interactions with the following:

• Anticoagulants: Enhances their effects, increasing the risk of bleeding.
• Antihypertensives (e.g., ACE inhibitors, ARBs): Reduces their efficacy and increases the risk of renal impairment.
• Acetylsalicylic Acid (Low-Dose Aspirin): Interferes with its anti-platelet effect.
• Lithium and Methotrexate: Clearance is reduced, leading to elevated plasma levels and potential toxicity.
• Oral Hypoglycemic Agents: Inhibits their metabolism, increasing the risk of hypoglycemia.
• Antacids (Magnesium Hydroxide): Significantly increase Mefenamic Acid absorption.
• Mifepristone: Administration must be separated; NSAIDs should not be taken for 8–12 days following mifepristone.
• Alcohol: Consumption may increase the risk of gastrointestinal bleeding.

How Benostan Works at the Biological Level

Benostan's mechanism of action is local and multi-targeted, engaging three distinct physiological domains. The active phytochemicals function as non-selective modulators of key enzymes, including Cyclooxygenase (COX) and Lipoxygenase (LOX), within the Arachidonic Acid Cascade. This enzymatic interference reduces the output of pro-inflammatory mediators, which results in a subsequent modulation of pathway activity and contributes to dampened physiological responsiveness in the localized tissue.

Concurrently, the mechanism influences endothelial cells, normalizing microvascular permeability. This physiological effect directly results in reduced fluid extravasation into the surrounding tissue space, thereby limiting the accumulation of extravascular fluid and maintaining localized tissue volume. The third mechanism involves a dual function of chemical and physical preservation. Polyphenols act as antioxidants, neutralizing Reactive Oxygen Species (ROS) and preventing the oxidative stress that initiates cellular damage, while waxy components provide an emollient barrier that maintains the tissue's structural integrity and resistance to external stressors.

Administration Guidelines for Benostan (Mefenamic Acid)

Benostan is an oral medication available in 250 mg capsules, 500 mg tablets/caplets, and a liquid suspension (50 mg/5 mL). Its usage is governed by established rules defining the dose, frequency, and duration of therapy, ensuring a standardized approach to its administration.

---

Administration Scope

Instruction	Detail
Route of administration	The medication is administered orally (by mouth) only.
Dosing schedule	Initial Dose: 500 mg once. Maintenance Dose: 250 mg.
Timing in relation to meals	Must be taken with food or milk or with a full glass of water to mitigate irritation.
Age-group administration rules	Not typically recommended for acute pain in children under 14 years of age. Lowest effective dose for shortest duration for older adults.

---

Instruction Classifications (High-level)

Classification	Detail
Administration method type	Oral.
Frequency pattern	As-needed (PRN) for symptoms, with a maximum frequency of every 6 hours.
Guideline basis	Established clinical guidelines.
Use-context constraints	Duration limits apply: max 7 days for acute pain; max 2 to 3 days for dysmenorrhea.

---

Resulting Procedural Structure

The fixed administration schedule requires taking the maintenance dose every 6 hours as needed for symptoms, resulting in a maximum frequency of four times daily. Treatment must align with the principle of using the lowest effective dose for the shortest duration possible. Specific time constraints apply: use for acute pain is limited to a maximum of 7 days, and for primary dysmenorrhea, treatment should not exceed 2 to 3 days, beginning at the onset of bleeding and associated symptoms. The liquid suspension may require shaking to ensure accurate dose measurement.

Research Evidence / Overview of Studies for Benostan

Evidence for use in Primary Dysmenorrhea (Menstrual Pain)

Research exploring how symptoms change over time in conditions characterized by fluctuating or episodic manifestations like primary dysmenorrhea has included Randomized Controlled Trials (RCTs) and systematic reviews. The research examined outcomes related to physical discomfort, such as measuring changes in pain intensity over short periods, usually across one or two menstrual cycles.

Studies explored how outcomes related to physical discomfort evolved in the observed populations. Research highlights changes measured during the study period, noting changes in patient-reported outcomes describing perceived discomfort. Despite this body of evidence, long-term effects are not fully established; the follow-up durations were limited, and data for certain groups are still emerging, such as those with specific co-occurring conditions.

---

Evidence for use in Acute, Mild-to-Moderate Pain

For acute, mild-to-moderate pain, such as that experienced after a minor procedure, the research available focuses on short-term outcomes. Studies mainly involve single-dose Randomized Controlled Trials (RCTs) and systematic reviews. Research explored short-term symptom changes, with outcomes capturing phases of heightened symptom activity, such as the total amount of pain relief reported by patients over the immediate four to six hours following a dose.

Research highlights changes measured during the study period, providing insight into short-term changes. However, the evidence is limited, as the results apply only to the populations studied and largely concentrate on a single type of short-term pain. Follow-up durations were limited; research provides limited information for long-term outcomes since assessments typically concluded within a few hours of drug administration.

---

What is Still Uncertain in the Research Record

The current research presents several areas where certainty remains low. A primary gap is the limited information for long-term outcomes, as research has focused heavily on acute and short-term changes. Additionally, comparative evidence is lacking for certain pain types, and subgroup findings are uncertain, particularly for older adults or individuals with existing health issues who were not the primary focus of the initial clinical trials. The sample sizes were modest in some key studies, and this may affect the precision of the findings reported.

Key Studies & References Mefenamic Acid Monograph - NIH MedlinePlus

Common questions about Benostan (FAQ)

Q: What are the most frequently reported side effects of Benostan?

Official regulatory documents list common side effects that may occur during the use of this medicine. These frequently reported events often include gastrointestinal discomfort, such as nausea or diarrhea, as well as general issues like headache or dizziness. Serious adverse events are detailed separately in the safety information section.

Q: Does Benostan cause tiredness or affect energy levels?

According to the official product information, effects on the central nervous system have been reported. These reports include symptoms such as dizziness or drowsiness. Regulatory warnings exist to inform individuals about these potential effects.

Q: What does regulatory information say about Benostan and alcohol consumption?

Regulatory warnings explicitly state that the consumption of alcohol may increase the risk of gastrointestinal bleeding while using this medicine. This is a common precaution associated with this class of drug due to its effect on the stomach lining.

Q: How quickly can a person generally expect Benostan to start providing an effect?

Pharmacokinetic data, which tracks how the drug moves through the body, describes the period when the maximum concentration of the active ingredient is typically achieved within a specified time frame after administration. This information helps define the typical expected onset of action.

Q: How long does the effect of a single dose of Benostan typically last?

The general period for which a single dose provides therapeutic concentrations is determined by the drug's half-life. The maximum recommended frequency for taking the medicine is established based on this pharmacological data.

Q: Is Benostan generally considered appropriate for use by elderly patients?

Official regulatory guidance describes the principle of using the lowest effective dose for the shortest possible duration when the medicine is administered to older adults. This cautious approach is taken due to the potential for increased risk in this population.

Q: What is the official information regarding the use of Benostan during pregnancy or while breastfeeding?

The official labeling states that the medicine is not recommended for use during the third trimester of pregnancy. For breastfeeding mothers, information on whether the drug is excreted in human milk is included, and healthcare professionals are advised to exercise caution.

Q: Has Benostan been studied for safety and use in pediatric populations?

Regulatory documents define specific age restrictions for the use of Benostan. The safety and effectiveness for certain younger pediatric age groups have not been established through research.

Q: Can people with pre-existing conditions like liver or kidney issues use Benostan?

Regulatory information notes that caution or specific clinical monitoring is required for individuals with pre-existing hepatic (liver) or renal (kidney) impairment. The need for supervision is due to how these organs process and eliminate the medicine.

Q: Are there any known long-term side effects associated with continuous use of Benostan?

Official regulatory documents detail specific safety concerns associated with continuous long-term use. These concerns include the potential for ocular toxicity and cumulative cardiovascular risks. The official information notes that these concerns may be a basis for ongoing safety evaluation.

Q: What are the official guidelines about taking Benostan with common pain relievers?

Regulatory guidance explicitly addresses the risks of co-administration with other nonsteroidal anti-inflammatory drugs (NSAIDs) and notes potential interference with the anti-platelet effect of low-dose aspirin. The regulatory documents also include information regarding the interaction profile with non-NSAID pain relievers.

Q: Does Benostan interact with any common over-the-counter cold medicines?

Regulatory documents may caution against co-administration with certain common over-the-counter cold products. This is often due to the risk of combining ingredients that could affect blood pressure or increase bleeding risk.

Q: What does official guidance suggest should be done if a dose of Benostan is missed?

Official instructions typically describe that taking a double dose to compensate for a missed dose is not recommended. The guidance generally indicates resuming the normal dosing schedule instead.

Q: Is Benostan known to affect sleep or cause insomnia?

Regulatory labels may list sleep disturbances or insomnia as reported adverse reactions affecting the nervous system. If these effects are experienced, they are listed as a potential side effect.

Q: Is there any known risk of dependency or addiction with long-term use of Benostan?

Official regulatory information confirms that Benostan is classified as a non-narcotic medicine. Therefore, it is not associated with the risk of addiction or physical dependency.

Q: Is it safe to drive or operate heavy machinery while taking Benostan?

Regulatory documents include a clear warning noting the need for caution when engaging in activities that require alertness. This is due to the potential for reported central nervous system effects like dizziness or changes in vision.

Q: What are the general rules about stopping the use of Benostan?

Regulatory documents emphasize the principle of using the medicine for the shortest possible duration necessary. This principle defines the intended end-point for therapy, which is related to symptom management and regulatory duration limits.

Q: Why is Benostan classified as a prescription-only drug?

The medicine is classified as Prescription-Only due to the nature of its potential risks and side effects. This status ensures that use is supervised by a clinician to manage safety concerns and duration limits.

Q: Is it true that Benostan may cause changes in appetite or body weight?

Regulatory labels may list metabolic or nutritional disorders as reported side effects. These can sometimes include changes in appetite or fluid retention, which may influence body weight.

Q: What happens if someone accidentally takes more Benostan than the prescribed amount?

Regulatory documents provide explicit details regarding the symptoms associated with an overdose. Regulatory documents state that immediate medical attention is necessary if an accidental overdose occurs.

Q: Is Benostan available as a generic medicine?

Official regulatory databases, such as those maintained by the NIH and FDA, confirm the existence of generic equivalents for the active ingredient, Mefenamic Acid.

How to Store and Dispose of Benostan (Mefenamic Acid)

Official regulatory guidelines dictate specific conditions for storing and disposing of Mefenamic Acid to maintain product integrity and safety.

---

Storage Conditions

Detail	Requirement
Temperature	Store at controlled room temperature, not exceeding 30 C.
Protection	Protect from light and excess moisture; do not store in the bathroom.
Container	Keep in the original package with the container tightly closed.
Child Safety	Must be stored out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Mefenamic Acid should be disposed of using a drug take-back program whenever possible. If a take-back option is unavailable, the medicine should be mixed with an unappealing substance, placed in a sealed bag, and discarded in the household trash. Do not dispose of this medication by flushing it down a toilet or sink, as it is not on the official flush list.